Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ejaculation-Preserving Versus Conventional Dual Wavelength Diode Laser Vaporization of the Prostate (EP-TUVP)

16. august 2026 opdateret af: ALI KAMAL M. SAMI

Ejaculation-Preserving Versus Conventional Dual-Wavelength Diode Laser Vaporization of the Prostate: A Randomized Comparative Study With 12-Month Follow up

Surgery to relieve urinary blockage caused by an enlarged prostate works well, but most men lose antegrade ejaculation afterwards, because semen passes backwards into the bladder instead of forwards. For sexually active men this is an important concern and a common reason for delaying or refusing surgery.

This study compared two ways of performing the same operation, laser vaporization of the prostate using a dual-wavelength diode laser. In the conventional technique, prostate tissue is removed from the bladder neck all the way to the verumontanum. In the ejaculation-preserving technique, the surgeon deliberately leaves a 10 mm rim of tissue at the bladder neck untouched, and another 10 mm of tissue just before the verumontanum untouched, while removing the blocking tissue in between. Everything else about the operation, including the laser settings, was the same.

Men were assigned to one of the two techniques by a computer-generated random sequence. They were assessed before surgery and again at 7 to 14 days, 1 month, 3 months, 6 months and 12 months after surgery.

The main question was how many men still had antegrade ejaculation 3 months after surgery. The study also compared urinary symptoms, urine flow rate, residual urine volume, prostate size, erectile function, complications and patient satisfaction, to find out whether preserving ejaculation costs anything in terms of relieving the urinary blockage.

Studieoversigt

Detaljeret beskrivelse

BACKGROUND

Loss of antegrade ejaculation follows conventional transurethral resection or vaporization of the prostate in the majority of men. Two anatomical regions are considered central to this: the internal urethral sphincter at the bladder neck, which prevents retrograde passage of semen, and the paracollicular and supracollicular tissue around the verumontanum, which contributes to the emission phase. Techniques preserving one or both regions have been described across several endoscopic platforms, but evidence specific to the dual-wavelength diode laser is limited and follow-up in previous work has been short.

OBJECTIVE

To determine whether an ejaculation-preserving technique of dual-wavelength diode laser vaporization of the prostate preserves antegrade ejaculation without compromising relief of bladder outlet obstruction, and whether any benefit is durable to 12 months.

DESIGN

Prospective, randomized, single-centre comparative study conducted at the Department of Urology, Royal Hospital, Sulaymaniyah, Kurdistan Region, Iraq. Allocation followed a computer-generated random sequence, with assignments concealed in sequentially numbered opaque sealed envelopes opened after consent. Participants were not informed of their allocation. The operating surgeon was necessarily aware of allocation.

INTERVENTION

All procedures were performed by a single surgeon under spinal or general anaesthesia, using a 22 Fr continuous-flow laser cystoscope sheath with normal saline irrigation. Energy was delivered by a Ceralas dual-wavelength diode laser system (biolitec biomedical technology GmbH, Jena, Germany) emitting simultaneously at 980 nm and 1470 nm, through a bare-tip fibre in continuous-wave mode at a total power of 140 W. Laser wavelength, fibre type, emission mode and power setting were identical in both arms.

Conventional arm: vaporization proceeded from the bladder neck to the verumontanum in the standard fashion, including tissue at the bladder neck and immediately proximal to the verumontanum, until a wide channel was created.

Ejaculation-preserving arm: no vaporization was performed within 10 mm distal to the bladder neck, and no vaporization was performed within 10 mm proximal to the verumontanum. Between these two margins, the lateral lobes, median lobe and anterior tissue were vaporized to the same endpoint as in the conventional arm. Adherence to both margins was recorded prospectively in every case.

ASSESSMENTS

Participants were assessed at baseline and at day 7 to 14, 1 month, 3 months, 6 months and 12 months. Symptoms were quantified with the International Prostate Symptom Score and its quality-of-life item, and erectile function with the five-item International Index of Erectile Function. Uroflowmetry was accepted only with a voided volume of at least 150 mL. Post-void residual volume and prostate volume were measured by transabdominal ultrasound. Ejaculatory status was recorded as a binary patient-reported outcome: presence or absence of any antegrade ejaculate during sexual activity since the preceding visit. Complications were graded using the Clavien-Dindo classification.

ANALYSIS

Continuous variables were compared between arms with the Mann-Whitney U test and within arms against baseline with the Wilcoxon signed-rank test. Proportions were compared with the two-sided Fisher exact test, with risk differences reported using Newcombe hybrid-score 95 percent confidence intervals. No imputation was performed. Analysis was restricted to participants with complete records at every scheduled visit.

NOTE ON REGISTRATION

This trial was registered retrospectively. The protocol, including the primary endpoint, the secondary endpoints and the two 10 mm technical margins, was submitted to and registered by the Scientific Committee of the Department of Clinical Sciences, College of Medicine, University of Sulaimani (number 28, 25 February 2025) and approved by the Ethics Committee of the same institution (number 62, 2 March 2025). Public registry registration was not undertaken before enrolment because the requirement was not appreciated at the time. No outcome measures, eligibility criteria or analysis definitions were altered after the study began.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

119

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Kurdistan
      • Sulaymaniyah, Kurdistan, Irak, 46001
        • Royal Hospital, Department of Urology

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Male, aged 50 years or older
  • Lower urinary tract symptoms attributable to benign prostatic obstruction
  • International Prostate Symptom Score of 16 or more
  • Maximum urinary flow rate below 15 mL/s on a uroflowmetry study with a voided volume of at least 150 mL
  • Prostate volume between 30 and 150 cc on transabdominal ultrasound
  • Indication for surgery after failure of or intolerance to medical therapy
  • Preserved antegrade ejaculation at baseline
  • Currently sexually active
  • Willing and able to attend all scheduled follow-up visits
  • Written informed consent, including specific consent to discussion and recording of ejaculatory function

Exclusion Criteria:

  • Suspected or confirmed prostate cancer
  • Prostate-specific antigen above the age-specific reference range without a benign explanation
  • Neurogenic bladder
  • Urethral stricture
  • Bladder stones
  • Previous prostatic or urethral surgery
  • Absent antegrade ejaculation at baseline
  • Erectile dysfunction sufficient to preclude sexual activity

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: conventional tuvp
Conventional dual-wavelength diode laser vaporization of the prostate. Vaporization proceeded from the bladder neck to the verumontanum in the standard fashion, with removal of obstructing adenoma including the tissue at the bladder neck and immediately proximal to the verumontanum, until a wide channel was created
Transurethral vaporization of the prostate using a Ceralas dual-wavelength diode laser (biolitec biomedical technology GmbH, Jena, Germany) emitting simultaneously at 980 nm and 1470 nm, bare-tip fibre, continuous wave, total power 140 W, delivered through a 22 Fr continuous-flow laser cystoscope sheath with normal saline irrigation, under spinal or general anaesthesia. Adenoma was vaporized from the bladder neck to the verumontanum without preservation margins.
Eksperimentel: Ejaculation-Preserving TUVP (EP-TUVP)
Ejaculation-preserving dual-wavelength diode laser vaporization of the prostate. No vaporization was performed within 10 mm distal to the bladder neck, preserving the circular muscle fibres of the internal sphincter, and no vaporization was performed within 10 mm proximal to the verumontanum, preserving the paracollicular and supracollicular tissue. Between these two margins, the lateral lobes, median lobe and anterior tissue were vaporized to the same endpoint as in the conventional arm. Laser settings were identical to the comparator arm.
Identical equipment, laser settings and anaesthesia to the comparator intervention, with two preservation margins: no vaporization within 10 mm distal to the bladder neck and none within 10 mm proximal to the verumontanum. Adequacy of the mid-prostatic channel was confirmed endoscopically at the end of the procedure. Adherence to both margins was recorded prospectively for every case.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Preservation of antegrade ejaculation
Tidsramme: 3 months after surgery
Proportion of participants reporting the presence of any antegrade ejaculate during sexual activity since the preceding visit. Recorded as a binary patient-reported outcome (present or absent). All participants had antegrade ejaculation at baseline as an eligibility requirement.
3 months after surgery

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Durability of integrate ejaculation preservation
Tidsramme: 6 and 12 months after surgery
Proportion of participants reporting presence of any antegrade ejaculate, assessed as for the primary outcome, to test whether any benefit is sustained over time.
6 and 12 months after surgery
Change in international prostate symptom score IPSS
Tidsramme: Baseline, 3, 6, and 12 months after surgery
IPSS total score, range 0 to 35, where higher scores indicate more severe lower urinary tract symptoms. Change from baseline is reported.
Baseline, 3, 6, and 12 months after surgery
Change in IPSS quality of life score
Tidsramme: Baseline, 3, 6, and 12 months after surgery
Single-item IPSS quality-of-life question, range 0 to 6, where higher scores indicate worse bother from urinary symptoms.
Baseline, 3, 6, and 12 months after surgery
Change in maximum urinary flow rate (Qmax)
Tidsramme: Baseline, 3, 6, and 12 months after surgery
Maximum flow rate in mL/s measured by uroflowmetry, accepted only when voided volume was at least 150 mL. Higher values indicate better flow.
Baseline, 3, 6, and 12 months after surgery
Change in post-void residual urine volume
Tidsramme: Baseline, 3, 6, and 12 months after surgery
Post-void residual volume in mL measured by transabdominal ultrasound. Lower values indicate more complete bladder emptying.
Baseline, 3, 6, and 12 months after surgery
Change in prostate volume
Tidsramme: Baseline, 3, 6, and 12 months after surgery
prostate volume in cc measured by transabdominal ultrasound, using the prolate, elipsoid formula with percentage reduction from baseline calculated
Baseline, 3, 6, and 12 months after surgery
Change in erectile function (IIEF-5)
Tidsramme: Baseline, 3, 6, and 12 months after surgery
Five-item International Index of Erectile Function, range 5 to 25, where higher scores indicate better erectile function. Assessed as a control variable to distinguish ejaculatory from erectile outcomes. Face like, three, six, and 12 months after
Baseline, 3, 6, and 12 months after surgery
Complications graded by Clavien-Dindo classification
Tidsramme: From surgery to 12 months after surgery
Clavien-Dindo grade recorded per participant, from grade I (any deviation from normal course) to grade V (death), including in-hospital and all follow-up intervals.
From surgery to 12 months after surgery
Patient global satisfaction
Tidsramme: 3, 6, and 12 months after surgery
Patient-reported global satisfaction with the outcome of surgery on a 5-point scale, where 1 indicates very dissatisfied and 5 indicates very satisfied.
3, 6, and 12 months after surgery
Trifecta outcome
Tidsramme: 12 months after surgery
Composite endpoint requiring all three of: IPSS below 8, complete pad independence, and preserved antegrade ejaculation.
12 months after surgery
Operative time, catheterization time and hospital stay
Tidsramme: Day of surgery to hospital discharge, up to seven days
Operative time in minutes measured from insertion to withdrawal of the cystoscope, duration of postoperative catheterisation in hours, and length of hospital stay in hours.
Day of surgery to hospital discharge, up to seven days
Early post operative dysuria
Tidsramme: Day 7 to 14 and 1month after surgery
Dysuria severity on a visual analogue scale from 0 to 10, where higher scores indicate more severe dysuria, together with the duration of dysuria in days.
Day 7 to 14 and 1month after surgery
Re-treatment for benign prostatic obstruction
Tidsramme: Up to 12 months after surgery
Proportion of participants requiring any further surgical intervention for benign prostatic obstruction.
Up to 12 months after surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. oktober 2024

Primær færdiggørelse (Faktiske)

27. oktober 2025

Studieafslutning (Faktiske)

20. juli 2026

Datoer for studieregistrering

Først indsendt

16. august 2026

Først indsendt, der opfyldte QC-kriterier

16. august 2026

Først opslået (Faktiske)

20. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data underlying the published results, including baseline characteristics, operative details, and all follow-up outcome measurements, will be made available to qualified investigators.

IPD-delingstidsramme

Beginning 6 months after publication of the primary results and ending 5 years thereafter.

IPD-delingsadgangskriterier

Requests should be directed to the principal investigator and must include a methodologically sound proposal and a stated analysis objective. Data will be released after review of the proposal and completion of a data access agreement.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner